Kun Jin1, Shi Qiu1,2, Di Jin1, Xianghong Zhou1, Xiaonan Zheng1, Jiakun Li1, Xinyang Liao1, Lu Yang1, Qiang Wei1. 1. Department of Urology, Institute of Urology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. 2. Center of Biomedical Big Data, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract
BACKGROUND: Muscle-invasive bladder cancer (MIBC) with high tumor stages accounts for most bladder cancer patient mortality. Platinum-based chemotherapy provides insufficient survival benefits; however, immunotherapy is a promising option for MIBC. RESULTS: There were 31 differentially expressed IRGs that significantly correlated with the clinical outcomes of MIBC patients. A prognostic signature based on 12 IRGs (MMP9, RBP7, ADIPOQ, AHNAK, OAS1, RAC3, SLIT2, EDNRA, IL34, PDGFD, PPY, IL17RD) performed moderately in prognostic predictions with area under the curve (AUC) equal to 0.76. The high-risk patient group presented worse survival outcomes (hazard ratio 1.197, 95% confidence interval 1.103-1.299, p < 0.001). Furthermore, immune cell infiltration analysis showed increased tumor infiltration of macrophages in the high-risk group. CONCLUSION: This novel prognostic signature can effectively divide MIBC patients into different risk groups, allowing for intensive treatment of high-risk individuals who have worse predicted survival outcomes. METHODS: Bioinformatics analyses were conducted using the Cancer Genome Atlas (TCGA) database. Differentially expressed genes and survival-associated immune-related genes (IRGs) were analyzed through a computational algorithm and Cox regression. The potential mechanisms of IRG expression were explored with transcription factors, and a prognosis classification based on IRG expression was developed to stratify patients into distinct risk groups.
BACKGROUND:Muscle-invasive bladder cancer (MIBC) with high tumor stages accounts for most bladder cancerpatientmortality. Platinum-based chemotherapy provides insufficient survival benefits; however, immunotherapy is a promising option for MIBC. RESULTS: There were 31 differentially expressed IRGs that significantly correlated with the clinical outcomes of MIBCpatients. A prognostic signature based on 12 IRGs (MMP9, RBP7, ADIPOQ, AHNAK, OAS1, RAC3, SLIT2, EDNRA, IL34, PDGFD, PPY, IL17RD) performed moderately in prognostic predictions with area under the curve (AUC) equal to 0.76. The high-risk patient group presented worse survival outcomes (hazard ratio 1.197, 95% confidence interval 1.103-1.299, p < 0.001). Furthermore, immune cell infiltration analysis showed increased tumor infiltration of macrophages in the high-risk group. CONCLUSION: This novel prognostic signature can effectively divide MIBCpatients into different risk groups, allowing for intensive treatment of high-risk individuals who have worse predicted survival outcomes. METHODS: Bioinformatics analyses were conducted using the Cancer Genome Atlas (TCGA) database. Differentially expressed genes and survival-associated immune-related genes (IRGs) were analyzed through a computational algorithm and Cox regression. The potential mechanisms of IRG expression were explored with transcription factors, and a prognosis classification based on IRG expression was developed to stratify patients into distinct risk groups.
Entities:
Keywords:
The Cancer Genome Atlas; bioinformatics analysis; immune-related genes; muscle-invasive bladder cancer; prognostic signature
Authors: Lee A D Cooper; David A Gutman; Candace Chisolm; Christina Appin; Jun Kong; Yuan Rong; Tahsin Kurc; Erwin G Van Meir; Joel H Saltz; Carlos S Moreno; Daniel J Brat Journal: Am J Pathol Date: 2012-03-20 Impact factor: 4.307
Authors: Sanchita Bhattacharya; Sandra Andorf; Linda Gomes; Patrick Dunn; Henry Schaefer; Joan Pontius; Patty Berger; Vince Desborough; Tom Smith; John Campbell; Elizabeth Thomson; Ruth Monteiro; Patricia Guimaraes; Bryan Walters; Jeff Wiser; Atul J Butte Journal: Immunol Res Date: 2014-05 Impact factor: 2.829
Authors: Ya Guo; Yin Bin Zhang; Yi Li; Wang Hui Su; Shan He; Shu Pei Pan; Kun Xu; Wei Hua Kou Journal: Int J Genomics Date: 2022-05-26 Impact factor: 2.758
Authors: Haoyu Ren; Alexandr V Bazhin; Elise Pretzsch; Sven Jacob; Haochen Yu; Jiang Zhu; Markus Albertsmeier; Lars H Lindner; Thomas Knösel; Jens Werner; Martin K Angele; Florian Bösch Journal: Mol Ther Oncolytics Date: 2021-12-09 Impact factor: 7.200